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Abstract 
Guanylyl cyclase C (GCC) a receptor for bacterial diarrheagenic enterotoxins is 
expressed selectively by intestinal epithelium and is an endogenous downstream target of 
CDX2. The expression of GCC is preserved throughout the adenoma/carcinoma sequence 
in the colorectum. Detection of GCC expression by RT-PCR is currently being validated 
as a technique to identify occult lymph node metastases in patients with colorectal cancer 
(CRC) and for circulating cells in the blood for postoperative surveillance. Although 
GCC is widely expressed by well-differentiated CRC its expression in poorly 
differentiated CRC has not been evaluated. A tissue microarray was created from 72 
archival specimens including 44 poorly differentiated (PDC), 15 undifferentiated or 
medullary (MC), 10 signet ring cell (SRC) and 3 neuroendocrine (NE) CRCs. Matched 
normal colonic mucosa was used as a positive control. Immunohistochemical staining for 
GCC and CDX2 was evaluated as positive or negative based on at least a 10% extent of 
staining. Out of the 72 tumor samples 75%, 47%, 90% and 67% of the PDC, MC, SRC 
and NE tumors were positive for GCC and 75%, 40%, 90% and 100% of these subsets 
were positive for CDX2 respectively. There was excellent correlation between GCC and 
CDX2 expression on a case per case basis (p<0.0001). Immunopositivity for GCC was 
greater than 95% in a separately stained microarray series of well/moderately 
differentiated CRCs.  In conclusion, GCC expression is lost in a quarter of poorly 
differentiated and half of undifferentiated CRC. Therefore the utility of GCC expression 
as a diagnostic and prognostic marker for CRC may be questionable in poorly 
differentiated colorectal neoplasms. 
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Introduction 
 
Colorectal carcinoma (CRC) is the third most common cause of cancer death in 
the United States.1 CRC can be divided into well, moderately and poorly differentiated 
adenocarcinomas based on the histologic presence of glandular differentiation. By 
definition CRC is classified as being poorly differentiated (or high grade) if more than 
50% of the tumor is formed by non-gland forming neoplastic cells.2 Subtypes of  poorly 
differentiated CRCs include undifferentiated or medullary carcinomas (MC), signet ring 
cell carcinomas (SRC), neuroendocrine carcinomas (NE) and  poorly differentiated not 
otherwise specified (PDC).2 Approximately 20% of all CRC fall into the poorly 
differentiated category.3  
A number of immunohistochemical and PCR markers specific for intestinal 
epithelium have been characterized and their retention in many CRCs has been utilized 
for the identification of metastatic tumors, detection of occult lymph node metastases and 
for detecting circulating tumor cells in the peripheral blood.4-6 Guanylyl cyclase C (GCC) 
is an N-linked  glycoprotein receptor for heat stable enterotoxin that is expressed by 
intestinal epithelium.7,8 The intestine specific expression of the GCC promoter requires 
CDX2.9  GCC has been shown to be a sensitive and specific marker for CRCs,  and its 
expression is retained in the adenoma to adenocarcinoma sequence.10,11 Molecular studies 
to detect the presence of GCC have been proposed as a method of detecting occult 
micrometastases to regional lymph nodes in CRCs.12-15 To date, the expression of GCC in 
poorly differentiated CRCs has not been thoroughly investigated. 
CDX2 is a transcription factor expressed in intestinal epithelial cells and is 
thought to play a role in the differentiation and proliferation of intestinal epithelium.16  
Several studies have show CDX2 to be both a sensitive and specific marker of intestinal 
differentiation; furthermore, it appears to be overexpressed in CRC tumor cells compared 
with normal intestinal epithelium.17-19 While the majority of well and moderately 
differentiated CRCs stain strongly for CDX2, certain studies have shown that a lower 
proportion of poorly differentiated tumors express CDX2.20-21 
The focus of this study was to examine the pattern of staining of GCC expression 
in a large cohort of poorly differentiated CRCs and to correlate these findings with the 
expression of CDX2. 
 
Material and Methods 
Patients and samples 
Formalin-fixed paraffin embedded tissues from 72 specimens including 44 poorly 
differentiated (PDC), 15 undifferentiated or medullary (MC), 10 signet ring cell (SRC) 
and 3 neuroendocrine (NE) CRCs were collected from the archives of the Department of 
Pathology at the Rhode Island and Miriam Hospitals in accordance with Institutional 
Review Board approvals from both hospitals.  The written reports of all colon cancer 
patients diagnosed between the years 1984-2008 were reviewed and all cases classified as 
PDC, MC, SRC and NE were selected . Histological sections were reviewed by MR and 
BW and were reclassified based on the current WHO criteria.2          
                               
Tissue microarray construction 
Areas of pure invasive carcinoma were identified on hematoxylin-eosin-stained 
slides from each case.  In cases of PDC that showed focal well differentiated areas, only 
the poorly differentiated components were selected.  The corresponding areas on the 
paraffin embedded source blocks were identified and marked.  The source blocks were 
then cored and a 1-mm core was transferred to the “master block” using the Beecher 
Tissue Microarrayer (Beecher Instruments, Silver Spring, MD).  Approximately three to 
five tissue cores of tumor were obtained for each case.  Additionally, two to three cores 
of histologically normal adjacent colonic mucosal tissue were obtained and arrayed in the 
same manner. Whole sections of five cases of PDC which had focal well differentiated 
areas were also assessed. In addition a tissue microarray (TMA) constructed previously 
containing 111 cases of primarily moderately to well differentiated CRC was assessed.22 
 
Immunohistochemistry  
Immunohistochemical staining for each antigen was performed on 6 micron 
paraffin sections of each of the TMA masterblocks.  The TMA sections were stained for 
CDX2 (mouse antibody, clone CDX2-88, 1:50, Biogenex, San Ramon, CA) and GCC 
(rabbit polyclonal, Gift from SA Waldman, first described by Birbe et al11) were 
performed using the Dako Autostainer with the Dako Envision Plus kit or manually with 
the Dako Envision Plus kit. The slides were counter stained with hematoxylin and 
dehydrated in graded alcohols through to xylene and coverslipped.  Normal colonic 
mucosa served as a positive control both CDX2 and GCC.  
 
Immunohistochemical assessment 
The immunohistochemical stains were scored using a two-tiered scoring system: 
positive or negative. A positive score required moderate to strong staining of more than 
10% of the tumor cell population, whereas a negative score included tumors with focal 
(less than 10%) or weak staining.. This cutoff was reached based on personal experience 
and allowed for minimal interobserver variability in the scoring. BW and MR 
independently scored each of the sections without knowledge of the histologic diagnosis 
or staining pattern with the other marker. There was a high correlation between the two 
scores and in the few discrepant cases, a consensus was reached after joint review.  
 
Statistical analysis  
Staining for GCC and CDX2 was compared between well differentiated CRCs 
and PDC, MC, SRC and NE using Fischer’s exact test. Correlation between GCC 
staining and CDX2 staining and the clinicopathologic comparison of MC and PDC was 
also analyzed using Fischer’s exact test. Two-tailed P values of 0.05 or less were 
considered to be statistically significant. 
 Results 
The clinicopathologic characteristics of the 72 cases of CRC are summarized in 
Table 1. The MC group had the highest mean age at the time of surgery (76yrs) as 
compared to the SRC, PDC and NE groups which were 71yrs, 68yrs and 62yrs 
respectively. The majority of patients with MC (87%), SRC (80%) and NE (67%) were 
female whereas only 45% of patients with PDC were female. The majority of tumors 
occurred on the right side in the MC (73%), SRC (80%) and NE (67%) groups whereas 
PDC was right sided in only 45% of cases. 
An example of each of the tumor types studied, PDC, MC, SRC and NE is shown 
in Figure 1. MC lacked glandular differentiation and exhibited solid sheets of neoplastic 
cells with a syncytial growth pattern and a moderate amount of eosinophilic cytoplasm.  
An intra-tumoral and peri-tumoral lymphocytic infiltrate was present. The PDC tumors 
were composed of at least 50% solid sheets or single neoplastic cells.  Typically the 
tumor cells were more pleomorphic than the MC group.  SRC were composed of at least 
50% of cells with prominent cytoplasmic mucin and characteristic displacement of the 
nucleus. NE exhibited a typical neuroendocrine H&E appearance in combination with 
strong positivity for at least one neuroendocrine marker.   
The normal colonic epithelium served as a positive control for GCC and showed 
typical apical membranous staining in all cases examined (Figure 2A). GCC stained the 
apical luminal membrane of the tumor cells in the well to moderately differentiated 
tumors (Figure 2B), whereas a predominantly cytoplasmic staining pattern was seen in 
the more poorly differentiated areas, which was most pronounced in the MC group 
(Figure 2C, 2D).  The SRC tumors exhibited a cytoplasmic with focal membranous 
staining (Figure 2E). NE tumors showed cytoplasmic and membranous staining (Figure 
2F). The pattern of CDX2 staining was nuclear in both the tumor cells and the normal 
colonic epithelium. 
Out of the 72 tumor samples 75%, 47%, 90% and 67% of the PDC, MC, SRC and 
NE tumors were positive for GCC and 75%, 40%, 90% and 100% of these subsets were 
positive for CDX2 (Table 2). In contrast all but two of the 111 moderately to well 
differentiated cases examined stained strongly for both GCC and CDX2. There was 
excellent correlation between GCC and CDX2 expression on a case per case basis 
(p<0.0001). GCC staining was more commonly lost in MC as compared to PDC 
(p=0.025). Several separately stained whole sections from five tumors showing areas of 
both well and poorly differentiated components were also examined. Positive GCC 
staining in the well-differentiated component and negative staining in the poorly 
differentiated areas was seen in these cases as depicted in Figure 3.   
 
Discussion 
GCC has been shown to be both a specific and sensitive marker of intestinal 
differentiation and is being investigated as a biomarker for occult lymph node metastases 
and circulating peripheral tumor cells.10-15 While essentially all well or moderately 
differentiated CRCs have been shown to stain positively with GCC there is only limited 
data on expression of GCC in PDC.10,11,14   Birbe et al. showed positive GCC staining in 
10 out of 10 PDC and 5 of 5 SRC and Buc et al. showed 5 out of 5 PDC stained with 
GCC.10,11 In contrast to the studies described above our study included a larger cohort of 
PDCs and also included the specific poorly differentiated subtypes: MC, SRC and NE. 
Our results indicate that a significant percentage of PDC (25%) and MC (53%) are 
negative for GCC expression as compared to well differentiated CRC. Interestingly, 90% 
of the SRC cases stained for both markers. There was also a strong positive correlation 
between CDX2 and GCC expression. This was not surprising as intestinal GCC 
expression requires a CDX2 binding element in the proximal promoter of CDX2.9 
One of the most important factors in guiding treatment in patients with colorectal 
carcinoma is regional lymph node metastases.23 Detection of micrometastases has import 
clinical implications and may lead to more aggressive chemotherapeutic treatment; 
however traditional techniques may fail to detect a significant proportion of lymph node 
metastases in CRC and lead to under-staging.24,25 Several studies have demonstrated the 
effectiveness of molecular studies using reverse transcriptase PCR for GCC in detecting 
occult micrometastases to lymph nodes in CRCs.12-15  Schulz et al. showed quantitative 
RT-PCR could be employed as a highly sensitive and specific method of detecting lymph 
node metastases.14 Carrithers et al also showed that by reverse transcriptase PCR GCC 
was present in peripheral blood samples of all patients with metastatic colorectal cancer 
and none of the control group and that the presence of GCC in peripheral blood samples 
may correlate with increased risk of recurrence or poorer prognosis.15 Bustin et al found 
that only 1/21 healthy patients had reverse transcriptase PCR positivity for GCC in the 
peripheral blood while 20/27 peri-operative patients with CRC were positive. In the same 
study CK19 and CK20, two markers typically positive in CRC, were found to be 
unreliable as indicators of circulating CRC tumors cells.6  Buc et al. also proposed GCC 
as a potential target for delivering chemotherapeutic agents directly to tumor cells by 
binding heat stable enterotoxin to an chemotherapeutic protein with subsequent GCC 
dependant tumor cell uptake.10  
Our findings suggest that if the primary CRC is poorly differentiated, there is a 
significant chance that the lesion would not express GCC and thus metastases to lymph 
nodes or circulating tumor cells in the peripheral blood may not be detected by molecular 
methods. This would also be of significance if future modalities utilize GCC as a target 
for delivery of proteins directly to tumor cells for imaging or chemotherapeutic purposes, 
as PDC or poorly differentiated components of well differentiated CRC might not express 
GCC.   
Finally, the observation that a significant portion of these PDCs and poorly differentiated 
components of well or moderately differentiated CRCs may lack staining with GCC is an 
important consideration when using this immunohistochemical  marker to aide in 
determining the primary site in a metastatic carcinoma of unknown origin.  
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Fig. 1. Hematoxylin and eosin stains of poorly differentiated adenocarcinoma (A), 
medullary carcinoma (B), signet ring cell carcinoma (C) and neuroendocrine carcinoma 
(D) (original magnification x200). 
 
 
Fig. 2. GCC staining pattern in normal colonic mucosa (A), well differentiated 
adenocarcinoma (B), poorly differentiated adenocarcinoma (C), medullary carcinoma 
(D), signet ring cell carcinoma (E), and neuroendocrine carcinoma (F) (original 
magnification x400). 
 
 
Fig. 3. GCC staining in a whole section of tumor displaying both well differentiated 
(right) and poorly differentiated areas (left) (original magnification x40). 
 
